HCQ-induced cardiotoxicity is rare, with 42 definitive cases published, predominantly in SLE or RA patients and one in scleroderma. We report HCQ-induced dilated cardiomyopathy in a woman with SS. Hydroxychloroquine routine diagnostics Plaquenil infertility Aug 29, 2014 Plaquenil, hydroxychloroquine HCQ, is an anti-malarial medication that has been proven to be useful in the treatment of patients with rheumatoid arthritis RA, systemic lupus erythematosus SLE and other inflammatory and autoimmune diseases. The molecular weight of hydroxychloroquine sulfate is 433.95, and molecular formula is C 18 H 26 ClN 3 O. H 2 SO 4. PLAQUENIL hydroxychloroquine sulfate tablets contain 200 mg hydroxychloroquine sulfate, equivalent to 155 mg base, and are for oral administration. Hydroxychloroquine Plaquenil®, especially at the higher standard dose of 400 mg per day, independently decreases the risk of cardiovascular morbidity in people with rheumatoid arthritis. Plaquenil (hydroxychloroquine) belongs to a group of medicines called quinolines. Methods: A 52 year old woman of Iraqi origin presented with a week’s history of dyspnoea at rest, palpitations, chest tightness, dry cough and peripheral oedema (New York Heart Association class IV) on a background of 3 months of progressive dyspnoea. Plaquenil cardiotoxicity Rx Side Effects New Plaquenil Guidelines and More - American., DailyMed - PLAQUENIL- hydroxychloroquine sulfate tablet Plaquenil turns hair whitePlaquenil effects on cell genesis Hydroxychloroquine HCQ, a common anti-rheumatic medication, can be cardiotoxic and cause systolic or diastolic heart failure HF. A 65 year old man presented with acute decompensated HF. He had a history of rheumatoid arthritis, and had been treated with hydroxychloroquine for the last 8 years. HYDROXYCHLOROQUINE PLAQUENIL CARDIOTOXICITY AN UNCOMMON.. Hydroxychloroquine reduces cardiovascular morbidity risk in.. Plaquenil hydroxychloroquine sulfate dose, indications.. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus a report of 2 cases and review of the literature Author links open overlay panel Jessica E. Nord MD a b c Prediman K. Shah MD a b c Renee Z. Rinaldi MD a b c Michael H. Weisman MD a b c Plaquenil is prescribed as a disease-modifier, in other words, to decrease pain, decrease swelling, and prevent joint damage and disability. It is not known how Plaquenil works but researchers believe that Plaquenil interferes with communication between cells within the immune system. Ultimately, it is thought to block proinflammatory pathways. Monitor patients for cardiomyopathy during PLAQUENIL therapy. Chronic toxicity should be considered when conduction disorders bundle branch block/atrio-ventricular heart block or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of PLAQUENIL may prevent life-threatening complications.